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Impact of Microvascular Complications on Outcome After Coronary Stent Implantations
in Patients With Diabetes
To the Editor: Bare metal stent implantation is less effective in
patients with diabetes than in patients without diabetes (1–3).
Microvascular complications have been identified as risk markers
for cardiovascular events in patients with diabetes (4–7). We
evaluated the impact of microvascular complications (nephropathy
and retinopathy) on the outcome after elective coronary bare metal
stent implantation in patients with type 2 diabetes.
A total of 283 consecutive patients with type 2 diabetes mellitus
who successfully underwent their first elective bare metal stent
implantation at our institution from January 2000 to June 2003
were included into the analysis. Diabetic retinopathy was detected
within one week before or after the procedure. Microalbuminuria
(protein excretion of 30 to 300 mg/24 h) was determined the day
before the procedure.
The principal characteristics of the 283 patients are summarized
in Table 1. At 12 months, major adverse cardiac events (major
adverse clinical event [MACE], i.e., death of any cause, nonfatal
myocardial infarction, repeat percutaneous procedure, and bypass
surgery) occurred in 34 of the 161 patients (21%) in the group
without microvascular complications, in 18 of the 45 patients
(40%) in the nephropathy group, in 22 of the 43 patients (51%) in
the retinopathy group, and in 25 of the 34 patients (73.5%) in the
group with both microvascular complications (p  0.001) (Fig. 1).
The influence of clinical, angiographic, and procedural variables on
Figure 1. Kaplan-Meier event-free survival at 12 months in four groups defined according to the presence of microvascular complications.
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MACE at follow-up was evaluated with a Cox regression analysis.
Variables entered into the model were as follows: the presence of
microvascular complications (as defined group without microvas-
cular complications, group with nephropathy, group with retinop-
athy, and group with both microvascular complications), age 70
years, sex, insulin-treatment, duration of diabetes 7 years, small
(2.75 mm) vessel, complex (B2/C) lesions, elective IIb/IIIa
inhibitors, left ventricular ejection fraction 40%, complete revas-
cularization, unstable angina, and multivessel stenting. Indepen-
dent predictors of MACE at follow-up were as follows: the
presence of diabetic nephropathy (hazard ratio [HR]  1.96; 95%
confidence interval [CI]  1.03 to 3.73; p  0.039), presence of
diabetic retinopathy (HR  3.38; 95% CI  1.73 to 6.60; p 
0.001), presence of both diabetic microvascular complications
(HR  6.28; 95% CI  3.33 to 11.84; p 0.001), insulin
treatment (HR  1.78; 95% CI  1.09 to 2.92; p  0.021), and
complete revascularization (HR  0.57; 95% CI  0.37 to 0.96; p
 0.019).
Patients with type 2 diabetes mellitus and proteinuria or
retinopathy have an increased risk of cardiovascular death (4–7).
The relative risks of cardiovascular mortality and morbidity asso-
ciated with the presence of microalbuminuria differ markedly
according to the presence or absence of retinopathy (7). In the
present study, we found that microvascular complications represent
a strong predictor of MACE after bare stent implantation in type
2 diabetic patients. In particular, the presence of both nephropathy
and retinopathy identifies a subgroup of diabetic patients with a
worse one-year outcome after elective bare stent implantation. The
results of the present study confirm and extend previous observa-
tions (8,9). Screening patients with diabetes for both nephropathy
and retinopathy before coronary procedures appears to be an
effective way to risk-stratify this group of patients and thus to focus
preventive measures. In the era of drug-eluting stent implantation,
these findings may be important to better interpret results and to
appropriately stratify patients undergoing percutaneous or surgical
treatments in prospective randomized trials.
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Table 1. Characteristics of Patients According to the Presence of Microvascular Complications
Group Without
Microvascular
Complications
(n  161)
Nephropathy
Group
(n  45)
Retinopathy
Group
(n  43)
Group With Both
Microvascular
Complications
(n  34) p Value
Age 62  9 62  10 65  12 64  9 0.24
Male (%) 124 (77) 39 (87) 28 (65) 27 (79.5) 0.34
Unstable angina (%) 36 (22.5) 10 (22.5) 5 (11.5) 6 (17.5) 0.16
Diabetes treatment 0.001
Non–insulin-requiring (%) 137 (85) 35 (78) 27 (63) 20 (59)
Insulin-requiring (%) 24 (15) 10 (22) 16 (37) 14 (41)
Duration of diabetes, yrs 7  7 9  8 14  12 11  8 0.001
Left ventricular ejection fraction (%) 59  8 59  9 54  12 54  13 0.018
Previous myocardial infarction (%) 76 (47) 22 (49) 26 (60.5) 16 (47) 0.25
Systemic hypertension (%) 110 (68) 32 (71) 34 (79) 27 (79.5) 0.50
Active smokers (%) 48 (30) 13 (29) 7 (16) 10 (29.5) 0.61
Serum creatinine, mg/dl (interquartile range) 1.09 (0.96–1.25) 1.17 (1.05–1.34) 1.02 (0.56–1.24) 1.02 (0.93–1.30) 0.033
Proteinuria, mg/24 h (interquartile range) 5 (0–25) 122 (45–325) 5 (0–25) 82 (41–123) 0.001
Glycosylated hemoglobin, % 7.4  1.5 7.7  1.4 8.1  1.5 8.5  1.7 0.003
Distribution of coronary artery disease (%) 0.090
Single-vessel 58 (36) 15 (33) 12 (28) 8 (24)
Double-vessel 74 (46) 20 (44.5) 16 (36.5) 14 (41)
Triple-vessel 29 (18) 10 (22) 15 (36.5) 12 (35)
Complex lesions, B2/C (%) 161/258 (62.5) 44/67 (65.5) 42/73 (57.5) 28/54 (52) 0.85
Diameter stenosis, %
Pre 81  15 84  15 82  15 80  15 0.75
Post 5  12 6  9 6  9 7  9 0.91
Vessel diameter, mm 2.95  0.59 2.94  0.54 2.83  0.51 2.87  0.54 0.43
Minimal lumen diameter, mm
Pre 0.67  0.51 0.67  0.50 0.68  0.51 0.74  0.51 0.51
Post 2.88  0.73 3.02  0.90 2.85  0.61 2.68  0.65 0.18
Lesion length, mm 11  5 11  4 12  6 12  4 0.32
Complete revascularization (%) 87 (54%) 26 (57) 18 (43) 13 (39.5) 0.27
Elective IIb/IIIa inhibitors (%) 73 (45.5) 14 (32) 12 (27.5) 16 (47) 0.077
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Letters to the Editor
Hibernating Myocardium, Apoptosis,
and a Simple Mathematical Task
We read with extreme interest the recent report by Elsasser et al.
(1). Their study reliably shows that both apoptotic and autophagic
cell death occur in hibernating myocardium and may be responsi-
ble for progressive clinical deterioration and lack of functional
recovery.
However, we are afraid the investigators may have made an
inaccurate estimate of apoptotic cell death rate. The researchers
indeed report an incidence of apoptosis of 0.002% (i.e., 1 of 50,000
cells). These data would suggest that at least 50,000 cells were
counted per patient in order to ascertain whether at least one was
apoptotic. But the investigators fail to clarify this issue thoroughly.
This point is particularly relevant when considering the electron
microscopy data. Considering the specific limitations of electron
microscopy we would imagine that the investigators evaluated not
more than 100 cells at electron microscopy per case. Yet assuming
100 cells examined per case and an apoptotic rate of 1 in 50,000,
the chance of randomly finding an apoptotic cell at the electron
microscope level in a single case would be 1 in 500. Accordingly,
the probabilty of 3 positive cases at electron microscopy would be
only 1 in 125 million.
In conclusion, we find the message given by Elsasser et al. (1)
extremely attractive and clinically relevant. However, we believe
that they might have underestimated the incidence of apoptotic
myocytes at confocal microscopy. We would greatly appreciate it if
the investigators could clarify these apparent inconsistencies.
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REPLY
We thank Dr. Abbate and colleagues for their interest in our work
(1). The major point of our recent publication is the fact that
autophagic cell death as described previously in patients with dilated
cardiomyopathy (2) is an important mechanism for killing myocytes
in hibernating myocardium and that apoptosis seems to be of less
importance. We are fully aware of the many technical problems that
might occur when attempting a quantitative analysis of the rate of cell
death, be it apoptosis, autophagic cell death, or necrosis (3). In our
experience, electron microscopy is not a suitable method for deter-
mining the rate of cell death, which has been emphasized by others as
well (4). Therefore, we use the confocal microscope. We analyze
entire sections, and as many cells as are available from the patient’s
material; we count the total number of nucleated myocytes per patient
and we determine the number of specifically labeled cells. This
information is then statistically analyzed on the basis of individual data
from each patient and ultimately expressed as a percentage. In a final
stage, results are summarized for an entire group of patients, and
different groups are compared by employing appropriate statistical
tests. Using this procedure each patient is weighted equally, even if
there are no labeled cells present.
We read with interest Dr. Abbate and colleagues’ work on
myocardial apoptosis in patients with unfavorable left ventricular
remodeling and we noticed the unusually high rates of apoptosis
reported for both infarcted myocardium and areas remote from the
infarct (5). Unfortunately, a precise indication of the total number
of myocytes examined is lacking from the description of methods,
rendering difficult an interpretation of these results. It would have
been more convincing had Dr. Abbate and colleagues used the
same criteria in his own work that he requests from ours.
There is no doubt, however, that myocyte death is a major
contributing factor to the deterioration of cardiac function in
pathological situations in the human heart, either in postinfarction
remodeling or in hibernating myocardium.
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